Antineoplastic drugs in extravasation (A–Z)
A
B
Bendamustineirritant with vesicant properties (ONS/ASCO) / vesicant (ESMO-EONS)Bleomycinnonvesicant (ESMO-EONS) / irritant (JSCN/JSMO/JASPO)BortezomibnonvesicantBrentuximab vedotinnonvesicantBusulfanvesicant
C
Cabazitaxelirritant with vesicant propertiesCarboplatinirritant with vesicant properties (ONS/ASCO) / irritant (ESMO-EONS, JSCN/JSMO/JASPO)CarfilzomibnonvesicantCarmustineirritant with vesicant properties (ONS/ASCO) / irritant (ESMO-EONS)Cisplatinirritant with vesicant properties (ONS/ASCO) / irritant (ESMO-EONS)Cisplatin (≥0.5 mg/ml)vesicantCladribinenonvesicantClofarabinenonvesicantCyclophosphamidenonvesicant (ESMO-EONS) / irritant (JSCN/JSMO/JASPO)Cytarabinenonvesicant
D
DacarbazineirritantDactinomycinvesicantDaunorubicinvesicantDaunorubicin (liposomal)irritantDocetaxelirritant with vesicant properties (ONS/ASCO) / vesicant (ESMO-EONS, JSCN/JSMO/JASPO)DoxorubicinvesicantDoxorubicin (liposomal)irritant
E
EpirubicinvesicantEribulinnonvesicantEtoposideirritant with vesicant properties (ONS/ASCO) / irritant (ESMO-EONS)Etoposide phosphatenonvesicant
F
G
I
IdarubicinvesicantIfosfamideirritantInotuzumab ozogamicinnonvesicantInterferonsnonvesicantInterleukin-2nonvesicantIrinotecanirritantIxabepiloneirritant
L
M
MechlorethaminevesicantMelphalanirritantMethotrexatenonvesicantMitomycin CvesicantMitoxantroneirritant with vesicant properties (ONS/ASCO) / vesicant (ESMO-EONS, JSCN/JSMO/JASPO) / irritant (ESMO-EONS)Monoclonal antibodiesnonvesicant
N
O
P
Paclitaxelirritant with vesicant properties (ONS/ASCO) / vesicant (ESMO-EONS, JSCN/JSMO/JASPO)Paclitaxel (albumin-bound)irritant with vesicant propertiesPemetrexednonvesicantPentostatinnonvesicant
R
S
T
TemsirolimusnonvesicantTeniposideirritantThiotepanonvesicantTopotecanirritantTrabectedinvesicantTrastuzumab emtansinenonvesicant